 |
|
 |
Prescription Drugs |
|
|
Stakeholder Opinions: Urinary Tract Infections
Ciprofloxacin Leads the Way
Publication Date July 2004
Publisher Datamonitor
Product Type Strategic Report
Pages 203
ISBN Number not applicable
Product Code DAT168
|
|
|
Summary
Introduction
Urinary tract infections are one of the most common bacterial infections across the seven major markets, second only to respiratory tract infections. As a result, such infections generate a significant proportion of antibacterial revenue and are the focus of key players and new entrants alike.
Scope of this report
- Commercial overview of the current UTIs antibacterial market in the US, EU and Japan
- A description of presentation, diagnostic and treatment practices in selected countries, based on discussions with numerous key opinion leaders
- Examination of how the patent expiry of Cipro has impacted this market and how niche products have gained leverage in the UTIs sector
- Investigation into why and how antibacterial companies may tailor marketing strategies to the community or hospital setting
Research and analysis highlights
UTIs are the second-most common type of bacterial infection, after those of the respiratory tract, with more than 35 million medically treated infections across the seven major markets each year. This translated into sales in excess of $1.1billion across key markets in 2003, with the majority of value derived from community management.The recent US patent expiry of Bayer's Cipro will result in the increased availability of cheaper versions of the leading UTI antibacterial. As a result, the recent decline in UTI market value is expected to continue over the next 2-3 years, as physicians switch to generic ciprofloxacin, despite the availability of once-daily Cipro XR.Community-based physicians across the major markets prescribe antibacterials for UTIs without knowledge of causative pathogens or specific site of infection. As a result, success in the community is driven by broad-spectrum activity, while the role for more specific therapies is currently limited in this sector.
Key reasons to read this report
- Gain an understanding of current routes of presentation, diagnosis and treatment practices in key economic markets
- Learn about the key antibacterials prescribed for treating UTIs, the strengths and weaknesses of each and unmet needs in treating such infections
- Find out how patent expiry has impacted this sector, and how reformulation strategies may prevent generic incursion
|
Content
- Chapter 1 Executive Summary
- Scope of the analysis
- Datamonitor insight into the community-acquired RTI market
- Urinary tract infections are the second most common type of bacterial infection, after those of the respiratory tract, with more than 35 million medically treated infections across the seven major markets each year (Stakeholder Insight: Bacterial Infection Epidemiology Database, 2003 - IMHC0067). This translated into sales in excess of $1.1 billion across key markets (US, Japan, UK, France, Italy and Spain) in 2003 (Stakeholder Insight: The Hospital Antibacterial Market, 2003 - DMHC1919; Midas Medical Data, IMS Health, April 2004), with the majority of value derived from community management.
- The US patent expiry of Bayer's Cipro (ciprofloxacin) will result in the increased availability of cheaper versions of the leading UTI antibacterial. As a result, the recent decline in UTI market value (CAGR 2001-03 = -0.28%) is expected to continue over the next two to three years, as physicians switch to generic ciprofloxacin, despite the availability of once-daily Cipro XR;
- Despite the availability of effective pathogen-specific UTI diagnostics, such as Osmetech's "eNose" technology, community-based physicians across the major markets still prescribe antibacterials for UTIs without knowledge of causative pathogens or specific site of infection. As a result, success in the community is driven by broad-spectrum activity and the role for more specific therapies is currently limited in this sector.
- Key metrics
- Chapter 2 Disease Definition And Epidemiology
- Introduction
- The urinary system
- Epidemiology
- Overview
- Urinary tract infections by gender
- Women
- Men
- Urinary tract infections by age
- Pediatrics
- Etiology
- Nosocomial infections and resistance
- Disease definition
- Complicated/uncomplicated urinary tract infections
- Recurrent urinary tract infections
- Re-infection
- Relapse
- Urethritis
- Cystitis
- Pyelonephritis (kidney infection)
- Asymptomatic urinary tract infection (bacteriuria)
- Acute urethral syndrome
- Chapter 3 Presentation And Diagnosis
- Presentation
- Referral
- Reasons for hospitalization
- Nosocomial UTIs
- Diagnosis
- Physical examination
- Urine samples
- Collection
- Dipstick tests
- Urinalysis
- Gram stain
- Urine culture
- Imaging techniques
- Ultrasound
- Nuclear scans
- Magnetic resonance imaging (MRI) or computed tomography (CT)
- X-rays
- Cystoscopy
- Country comparison
- Unmet need in diagnosing UTIs
- Chapter 4 Market Analysis
- Market definition
- Market overview
- Treatment options
- Amoxicillin
- Amoxicillin and clavulanic acid
- Ciprofloxacin
- Gatifloxacin
- Levofloxacin
- Imipenem and cilastin
- Linezolid
- Norfloxacin
- Ofloxacin
- Trimethoprim-sulfamethoxazole
- Treatment options overview
- Broad-spectrum versus selective antibiotics
- Antibiotic resistance
- Contraindications of current UTI-therapies
- UK case study: treating pregnant women with lower UTIs
- Therapeutic choice
- Therapeutic choice by indication
- Therapeutic choice for specific indications
- Cystitis
- Urethritis
- Therapeutic choice by patient age and gender
- Therapeutic choice by physician type
- Chapter 5 Strategic Evaluation
- Ciprofloxacin, generic incursion and patent expiry
- Overview
- Augmentin case study: the impact of patent expiry
- US
- EU
- Physician prescribing and patent expiry
- Cipro XR
- Comparing the hospital and community sectors
- Market overview
- Hospital versus community pricing differences
- Marketing in the community and hospitals
- Targeting for large versus small companies
- UTIs and the antibacterial lifecycle
- The importance of UTIs
- Product positioning and indication approval
- Niche UTI products
- Appendix A
- Drug key facts
- Opinion leader transcripts
- US key opinion leader
- 1. Presentation
- 2. Diagnosis
- 3. Treatment
- German key opinion leader
- 1. Epidemiology
- 2. Presentation
- 3. Diagnosis
- 4. Treatment
- 5. Other issues
- UK key opinion leader
- 1. Epidemiology and definitions
- 2. Presentation
- 3. Diagnosis
- 4. Treatment
- 5. Other issues
- French key opinion leader
- 1. Presentation
- 3. Treatment
- Italian key opinion leader
- 1. Epidemiology and definitions
- 2. Presentation
- 3. Diagnosis
- 4. Treatment
- 5. Other issues
- Spanish key opinion leader
- 1 Epidemiology and definition
- 2. Presentation
- 3. Diagnosis
- 4. Treatment
- 5. Other issues
- List of tables
- List of figures
- Bibliography
- Bibliography
- Epidemiology
- Websites
- General
- Sources
- Appendix B
- About Datamonitor
- About Datamonitor Healthcare
- Report methodology
- Datamonitor Healthcare's therapy area capabilities
- About the infectious disease analysis team
- Datamonitor Healthcare's Consulting expertise
- Datamonitor's Therapeutic Consulting expertise
- Key therapy team members
- John Savopoulos, Lead analyst, Infectious Diseases
- David Abramson, Therapeutic Lead Consultant
- Disclaimer
|
|
|
